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NON-INVASIVE MONITORING OF LIPOFUSCIN: AN IMAGING 
TECHNIQUE PREDICTIVE FOR AGE-RELATED MACULAR 
DEGENERATION  
 
ERIN FLYNN 
ABSTRACT 
 This paper outlines the progression of age-related macular degeneration in the eye 
and discusses the diagnostic approaches and therapies used currently to treat this disease. 
Age-related macular degeneration has a complicated pathophysiology involving genetic 
and environmental factors. This paper focuses its attention on the role of lipofuscin 
accumulation in this disease. Lipofuscin in the eye refers to the bisretinoid products of 
the visual cycle. While lipofuscin accumulation is normal in healthy eyes, the excessive 
accumulation causes retinal dysfunction.  
Lipofuscin accumulation has been linked heavily not only to age-related macular 
degeneration but also juvenile macular degeneration, retinitis pigmentosa, Best’s 
Villiform disease, and many others. New techniques in ophthalmic research have 
evaluated the role of lipofuscin accumulation in such retinal genetic diseases. This paper 
proposes an approach to apply techniques such as quantified autofluorescence imaging 
and high-powered liquid chromatography of bisretinoids in the eye to track the role of 
lipofuscin accumulation in the progression of age-related macular degeneration.  
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INTRODUCTION 
Age-related macular degeneration (“AMD”) is the number one cause of blindness 
in the developed world.1 Risk factors include age, genetic variants, family history, 
smoking, cardiovascular disease, hypertension, obesity, and a diet low in omega-3 fatty 
acids and dark green leafy vegetables.2  
There are two distinct types of AMD: dry and wet. Dry affects the majority of 
AMD patients (85%) while wet is less common although much more severe.3  Dry AMD 
occurs as a result of scarring on the macula, without either fluid or blood.  Wet AMD 
occurs when blood vessels have grown in the macula.  Over the past decade, drug therapy 
has become highly successful in managing wet AMD; the prognosis with respect to 
severe, dry AMD is far less promising .4   
This paper will accomplish the following objectives:  
(1) Consider the manifestation of AMD (i.e., what is AMD), 
(2) Consider and analyze the causes and risk factors for AMD (i.e., what causes 
the malfunction that leads to the phenomenon); 
(3) Consider and analyze the physiological transformation from dry to wet AMD;  
(4) Discuss the diagnostic tools, techniques and limitations applicable to retinal 
analysis; 
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(5) Assess A2E, a bisretinoid component of lipofuscin, as a biomarker for 
progression of AMD and its use in the diagnostic process for AMD based 
upon mouse study; 
(6) Consider treatment potential for AMD.  This will review the current drug 
therapies for AMD and their efficacy and evaluate potential strategies to 
prevent progression to AMD; and 
(7) Consider the future of AMD research, therapies and potential for prevention 
(including gene therapy).  
 
 
 
THE MANIFESTATION OF AMD 
 
The progression of AMD begins with photoreceptor cells and the retinal pigment 
ephithelium (RPE).  To understand  the progression of AMD, it is helpful to begin with a 
brief description of eye anatomy.     
(1) MAMMALIAN EYE ANATOMY 
The mammalian eye consists of multiple layers.  The first layer is the outer layer, 
consisting of the sclera and cornea; these layers protect the eye, contain its shape, and 
focus light to the back of the eye.  The second layer consists of the uvea and iris.  
 3 
!
These act as a vascular layer and pigmented layer.5  The pigment in this layer 
restricts light entry into the eye and also absorbs stray light photons within the eye to 
reduce scatter. Next is the lens, which is a non-neural, multi-layer, biconvex structure that 
changes shape, permitting the eye to focus on objects.  The focused images are then 
formed on the retina.  The final layer consists of the retina and optic nerve.  These 
structures in the eye sense light and transmit messages to the brain as electrical impulses.6   
 
FIGURE 1. Diagram of the Eye. "Three Main Layers of the Eye" by Artwork by Holly Fischer - 
http://open.umich.edu/education/med/resources/second-look-series/materials - Eye Slide 3.  
 
The retina consists of two types of photoreceptors, rods in the peripheral retina 
and cones located in the macula in the posterior pole.  The fovea, a structure that is part 
of the macula, is the most sensitive part of the retina, being responsible for fine visual 
discrimination and color vision.7 Rods are responsible for dark adaptation and night 
vision.  Input from rods and cones travels to the visual system via the optic nerves and 
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posterior visual fibers.  Vision itself takes place in the brain. In contrast to the other 
structures of the eye, the retina and optic nerves are part of the brain.8    
The macula is a small (2.5 millimeter) structure located where light at the center 
of gaze is focused in the back of the eye by the cornea and lens.  The macula and its 
cones have the highest rate of oxygen consumption of any tissue in the body.9  This 
requires a circulation consisting of inner vessels derived from the central retinal artery 
and a separate outer circulation derived from the choricocapillaris, a dense capillary bed 
in the uvea. The latter (choroid) is the more significant source of macular nutrition 
because the macula is predominantly supplied by the central retinal artery; indeed the 
center of the macula, a region called the fovea centralis, contains only cones and is 
exclusively supplied by the choriocapillaris. A blood-ocular barrier exists for both retinal 
and choroidal circulations.  Retinal blood vessels are comprised of endothelial cells with 
tight junctions.  Choroidal vessels are separated from the retina by several layers of 
tissues known as Bruch’s Membrane and overlying retinal pigment epithelial (RPE) cells. 
These two layers of tissue share a fused basement membrane.10 The effect of the blood-
ocular barrier is to allow into the retina and the eye only those molecules and oxygen 
which are necessary to the function of the eye.  All other constituents of blood are 
excluded from the interior of the eye.  This arrangement in the eye is analogous to the 
blood-brain barrier.11 
 
Optimal retinal function requires tight control over flow of water, nutrients, 
oxygen and metabolic waste products into and out of the eye. The photoreceptor cells 
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shed their outer segments daily—which contain the waste products left over from the 
visual cycle, referred to as bisretinoids. Studies have linked the accumulation of 
bisretinoids to activation of the immune system and have shown the harmful effects these 
bisretinoids have on the function of photoreceptor and RPE cells.12 Several disorders 
adversely affect the degradation of these waste products and, accordingly, have the 
potential to impair vision or cause blindness.  One such dysfunction is AMD.13 
(2) AMD DYSFUNCTION 
Photoreceptor cells in the retina create metabolic waste. Since these cells are the 
most metabolically active of the body, there is a relatively high volume of metabolic 
waste. Extracellular waste accumulation is normal in all mammals.14  The RPE (described 
above) is a part of the retina lying external to the neural retina and in direct contact with 
the outer segments of the photoreceptors. It serves many important functions:  it provides 
oxygen and nutrients to the photoreceptors, absorbs stray light, recycles spent 
photopigment, and delivers metabolic waste from the photoreceptors to the capillary bed 
of the choroid. In healthy eyes, the RPE also manages bisretinoid accumulation without 
causing severe problems.15  In general, the RPE breaks down waste, excreting it back into 
circulation, and, with respect to those waste products that it can’t excrete, RPE sequesters 
and packages these wastes as drusen.16 Drusen come in different sizes and shapes, and 
consist of a heterogeneous group of cellular waste products, many of which produce 
inflammation.17   
 6 
!
 
Figure 2. Intermediates of the Retinoid Visual Cycle. "Visual cycle" by Krishnavedala - Own work.  
 
With age, lipofuscin  can accumulate—even in healthy subjects—as the RPE 
becomes less efficient at processing it.  However, certain people are more susceptible to 
waste accumulation.  In some cases, the ability of RPE to degrade lipofuscin break down 
and these individuals are more likely to show signs of dry, advanced AMD and 
scarring.18 When this happens, the RPE cells are compromised and the retina begins to 
die, leading to blindness. There are signs of disease at the retina but most markedly at the 
fovea. This leads to dry AMD, which can progress to wet AMD. However, the causes 
underlying the progression from dry to wet AMD aren’t known at this time.19  
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Figure 3. Risk Factors and the Progression of Age-related Macular Degeneration. Figure generated by the 
author.  
 
RISK FACTORS OF AMD 
 
The risk factors relating to AMD are controversial.  There appear to be several 
factors that contribute to its progression, including genetic predisposition, accumulation 
of lipofuscin, accumulation of drusen, local inflammation, and neovascularization (in wet 
form).20  
(1) GENETIC PREDISPOSITION 
Genetics are an important factor that appears to contribute to AMD. Individuals 
with a family history of AMD are more likely to develop AMD than those with no family 
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history.21  This finding is consistent with genetic research relating to other retinal 
diseases.  Some genes have been directly linked to retinal diseases with symptoms similar 
to AMD.22   
In studies, mutations associated with a gene that codes for the ATP-binding 
cassette transport protein in photoreceptor cells (gene is called ABCA4) have been linked 
to both dominant and recessive Stargardts disease.23  Stargardts is an inherited, autosomal 
recessive retinal dystrophy leading to blindness in the adult years. The mutation causes a 
dysfunctional ATP-binding cassette transporter protein. This protein rids the 
photoreceptor cells of the visual cycle waste products.24  Other genes such as ELOVL4, 
FIBL-6, APOE, and SOD2 have been linked to retinal diseases with similar 
manifestations in the macula to AMD.25 Genes most closely associated to AMD tend to 
affect the immune system’s complement cascade. For instance, a mutation in the 
complement factor’s H (CFH) gene has been hypothesized to cause 50% of AMD cases.26 
It seems genetic predisposition to AMD is most heavily dependent on mutations that alter 
or affect the body’s immune system; however, no genetic mutation has yet been proved 
to cause AMD. 
(2) LIPOFUSCIN 
As noted above, RPE cell dysfunction is an initial step of AMD progression.27 
The RPE cells lie along the retina. Their function is vital to the health of the 
photoreceptor cells. Lipofuscin accumulates outside the photoreceptor cells in the visual 
cycle, and RPE cells work to phagocytize and transport these vitamin A derivatives.28  
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In the healthy retina, photoreceptor cells capture photons and perceive light in 
what is called the retinoid visual cycle. This process involves an enzymatic pathway 
whereby the cells generate the “inactive” 11-cis-retinal chromophore of rhodopsin; 
rhodopsin is in its “active” form in darkness.29  The initial intermediate of this pathway, 
all-trans-retinal, is moved from the inner to the outer segment layer of the photoreceptor 
cells by an ATP cassette-binding transporter known as the ABCA4 transport or rim 
protein.30 All-trans-retinal is then converted enzymatically to all-trans-retinol or it is 
further oxidized to form the more reactive A2PE and its successor, A2E.31 All-trans-
retinol will go on to form 11-cis-retinol to be recycled back into the cytoplasm of the 
photoreceptor cell and the retinoid visual cycle.32  
In healthy eyes, these intermediate molecules of the visual cycle are engulfed by 
phagosomes from the RPE in the outer segment layer, but some collect in the lysosomes 
of the RPE cells. These cells are unable to breakdown the intermediates, and the 
inadvertent products of the visual cycle make up what is known as RPE lipofuscin.33 
Other cell types in the body generate lipofuscin in response to stress, but even healthy 
RPE cells accumulate lipofuscin. Though accumulation is related to age and light 
exposure, excessive amounts have been linked to retinal degenerative diseases such as 
rod-cod dystrophy, recessive Stargardt’s disease, Best vitelliform macular dystrophy, and 
AMD.34  
The inability of the RPE cells to metabolize these waste products leads to an 
accumulation of lipofuscin in the retina. Although associated with dysfunction of the 
RPE cells, environmental factors like exposure to visible and UVA light or high oxygen 
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levels in the eye can increase the accumulation of lipofuscin in the retina. While 
excessive amounts of lipofuscin in the eye is linked to retinal disease, lipofuscin 
accumulates in healthy retinas and increases with age until it generally plateaus at around 
the age of 70 in normal patients.35 Furthermore, lipofuscin doesn’t include a single 
bisretinoid in the visual cycle but a host of vitamin A derivatives; however, one 
bisretinoid in particular (A2E), the result of two all-trans retinal reacting with 
ethanolamine, is understood to be its main component and is used as an indicator of 
lipofuscin levels and retinal degeneration in research.36   
(3) DRUSEN 
Another component of AMD is the formation of drusen in the macula. Drusen are 
amorphous deposits of lipid, fatty proteins that occur in the retina—derived from waste 
that cannot be excreted by RPE. Drusen occur naturally in healthy eyes.37  However, 
excessive drusen can lead to AMD. Excessive lipofuscin in the retina has been linked to 
drusen formation—as residual lipofuscin accumulates and forms pockets of drusen in the 
eye.38 
There are two types of drusen: hard and soft. Hard drusen is common in the 
elderly population and doesn’t correspond to AMD development—these are generally 
small (1-63 microns in diameter) and spread apart in the retina.39 More concerning is soft 
drusen.  Soft drusen is larger than 125 microns in diameter or between 63 and 125 
microns in diameter with a visible thickness. While soft drusen can occur in non-AMD 
retinas (commonly observed in individuals over 60), the link between drusenogenesis and 
AMD is closely related to the activation of the immune system in AMD. It is notable that 
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AMD is rarely diagnosed in the absence of soft drusen.40 Size, number, and appearance 
of drusen determine the risk for AMD development in retinas. Soft, large, and/or 
clustered drusen is associated with choroidal neovascularization symptomatic of wet 
AMD.41   
 
 
Figure 4. Soft Drusen Pictured in Color Fundus and Fluorescein Angiography Images. Images above were 
obtained from a case with Doyne’s Honeycomb Dystrophy. This disease is associated with a single 
mutation in the EFEMP1 gene. This gene codes for an EGF-containing fibrillin-like extracellular matrix 
protein 1, fibulin 3 which is present in the fused basal lamina of the RPE and the Bruch’s membrane. Here, 
the accumulation of drusen has coalesced and initiated an inflammatory state. The right most image is a 
fluorescein angiography of the eye pictured on the left. This fluorescein angiography shows the resulting 
CNV, the small vessels and the leaking blood. Images provided by Dr. Thomas E. Flynn M.D. 
 
Drusen accumulates between the basal side of RPE cells and Bruch’s membrane 
in the retina (Figure 4).  Bruch’s membrane separates the retina (RPE and photoreceptor 
cells) from the primary capillary bed of the choroid. This barrier consists of two 
extracellular collagenous layers, the basement membranes of both Bruch’s and the RPE.42 
Bruch’s membrane has 5 layers. Extending from interior to exterior of the eye, these are: 
first, basement membrane of RPE, second, inner collagenous zone, third, central band of 
elastic fibers, fourth, outer collagenous zone, and, fifth, choriocapillaris basement 
membrane. Transport of nutrients and oxygen to the retina and movement of metabolic 
waste products from photo-receptors to the choroid occurs through Bruch’s membrane. 
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The deposition of the RPE cells’ membranous debris or extracellular material into this 
barrier makes up drusen.43  
Drusen accumulation leads to the vision loss that is symptomatic of AMD. 
Formation of drusen initially causes changes in color vision, contrast sensitivity, visual 
acuity within the central visual field, and spatiotemporal contrast sensitivity leading to 
vision loss. These drusen deposits cause the photoreceptor cells associated with the 
overlying RPE cells to die and create an interruption of the RPE cell monolayer.44 
Current research hypothesizes that drusen directly causes damage to the 
photoreceptor/RPE cells but also indirectly causes damage due to its activation of the 
immune system and associated inflammation.  
Drusen in AMD patients contains large amounts of proteins involved in the 
body’s complement system along with RPE cell-remnants.45 These proteins consist of 
dendritic cells (potent antigen presenting cells which are recruited solely by signals, 
chemokines and cytokines, of the immune system), tissue inhibitor of metalloproteinase 
3, immunoglobulins (antibody complexes), MHC class II antigens, factors of the 
complement cascade (most notably, the complement factor H associated with the CFH 
gene and the Y402H mutation noted above), and terminal pathway components 
(including the membrane attack complex—MAC; C5b-9). The factor C5b-9 is created by 
the immune cells to attack pathogens but is also detrimental to the RPE, photoreceptor, 
and choroidal cells.46  
In the past, researchers believed that because many components of drusen were 
synthesized primarily in the liver, the components had accumulated there from the 
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choroidal vasculature. However, now it is understood that the RPE cells create the 
accumulations found in drusen.47 The RPE cells have been shown to have a large amount 
of the mRNAs associated with the drusen components such as apolipoprotein E (ApoE), 
complement factors (C3, C5, and C9), and vitronectin (Vn). It was found that the injured 
RPE accounts for the majority of this complement factors and immune proteins found in 
drusen.    
It has been hypothesized that the drusen (initially an accumulation of RPE cell 
membrane debris) leads to AMD. This is due to the inflammation caused by the drusen. 
Some inflammatory components found in drusen are classic acute phase reactant, but 
most are components of the complement cascade or inhibitors of the membrane attack 
pathway of complement.48 Here, acute refers to the initial non-specific reaction of the 
immune system to a threat; drusen normally contains components that provoke a 
specialized immune response. This suggests that the development of drusen occurs over a 
period of years and develops into a state of chronic inflammation—never allowing the 
system to return to a state of tolerance. Lipofuscin, in addition to RPE cell components 
and immune system-associated proteins, has also been observed within small, early 
drusen, and some hypothesize that the presence of lipofuscin leads to RPE dysfunction 
and the development of AMD.49   
 
(4) NEOVASCULARIZATION   
Another process involved in AMD is choroidal neovascularization (CNV). This is 
the major cause of severe vision loss in patients with AMD. Choroidal neovascularization 
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is the creation of new and abnormal blood vessels originating from the choroidal blood 
vessels and growing through Bruch’s membrane into the space beneath the RPE 
monolayer.50 This may cause serum or blood to collect below the RPE, which can cause 
distortion of the macula and the introduction of a scotomata, a blind spot in the visual 
field.  CNV is the major cause of vision loss of AMD.  The new vessels from CNV bleed 
and form dense macular scars. Vessels associated with CNV are curled, weak, and 
leaky.51  
With the highest oxygen consumption per unit weight of all human tissues, the 
retina is extremely sensitive to damage and stress. It is vascularized by two independent 
circulatory systems: the choroid and retinal vessels. The retinal circulatory system 
provides oxygen and nutrients to the inner two-thirds of the retina while the outer third of 
the retina, which lies adjacent to Bruch’s membrane, is avascular but relies on the 
choroidal circulation for its nutrients and oxygen.52  
Endothelial cells lining the blood vessels in the healthy eye don’t react to 
neovascular or pro-angiogenic stimuli, and endothelial cell proliferation normally doesn’t 
occur in the retinal vessels.53 For angiogenesis to occur, there must be an over-activity of 
pro-angiogenic signaling (as in any system). The process of neovascularization involves 
an interplay between stimulators and inhibitors in which the stimulators win out.  
Neovascularization in the retina occurs in response to lack of oxygen (hypoxia) or 
ischemia (lack of blood flow). A lack of oxygen or blood supply is derived from two 
factors.  First, as the body ages, the RPE and other agents in the eye become less efficient 
at conducting oxygen to the photoreceptor cells.  Second, there can be other problems in 
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the body (beyond the eye) that slow the transmission of oxygen and blood.  For instance, 
high blood pressure, problems with circulation and heart/lung function can impair the 
optimal transmission of blood and/or oxygen.  These issues can be brought on or 
exacerbated by environmental issues, such as smoking.54  The impairment of hemoglobin 
oxygenation by carbon monoxide from inhaled cigarette smoke leads to tissue hypoxia.  
Other compounds in cigarette smoke may also act to stimulate the immune system in 
ocular tissues.   
Local inflammation is also implicated in the creation of new blood vessels. 
Neutrophils, macrophages, mast cells, and microglia are capable of releasing pro-
angiogenic factors like vascular endothelial growth factor (VEGF).55 VEGF and other 
pro-angiogenic factors released by the immune cells and distressed RPE cells signal to 
the endothelial cells to proliferate and create new blood vessels.  
 
PHYSIOLOGICAL TRANSFORMATION FROM DRY TO WET AMD 
 
 There is a high incidence of dry AMD—roughly 85% of AMD is dry, as 
compared to 15% of wet AMD.  However, among patients who suffer severe vision loss 
due to AMD, the percentages are roughly reversed—nearly 90% of AMD patients 
experiencing severe vision loss have wet AMD.56  All wet AMD starts with dry AMD; 
once the disease has progressed from dry to wet, it never reverses to dry again.  Due to 
the prevalence of vision loss associated with wet AMD, it is important to understand the 
progression of the disease. 
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The change from dry to wet AMD appears to be initiated by CNV across Bruch’s 
membrane and the RPE monolayer. The initiation of CNV is primarily caused by one or 
more of three main factors: VEGF stimulation, damage to Bruch’s membrane, and 
activation of macrophages. With advancing age, the Bruch’s membrane thickens.57  This 
thickening compromises and decreases the ability of the nutrients and oxygen to diffuse 
to the RPE cells.58 It should also be noted that this age-related thickening of Bruch’s 
membrane linearly coincides with the accumulation of lipofuscin in the retina.59 This 
thickening is hypothesized to be due to degeneration of the overlying RPE. In effect, RPE 
becomes less effective at degrading waste in its lysosomes with age. Due to Bruch’s 
membrane thickening, RPE cells are isolated from their source of nutrition. This, in turn, 
causes an increase of collagen and mineralized deposits in the elastic lamina (which 
correlate to increasing lipid content in Bruch’s membrane).60  
Changes due to RPE and Bruch’s thickening lead to a decrease in hydraulic 
conductivity that makes it more difficult for nutrients and oxygen to diffuse from the 
choroidal vascularization to the RPE cells. This stress causes the RPE cells to release 
VEGF, a pro-angiogenesis signal, as a stress response to initiate growth of the endothelial 
cells lining the choroid’s vessels.61 Furthermore, the change in thickness makes it more 
difficulty for RPE cells  to dispose of waste. However, CNV doesn’t occur without 
compromise of Bruch’s membrane.62  
In the healthy retina, the Bruch’s membrane separates the choroidal vessels from 
the RPE and helps transport water, nutrients, and macromolecules between the RPE and 
choroid. Only a weakened Bruch’s membrane will allow the growth of new vessels in 
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AMD.63  In AMD donor eyes where one eye was affected and the other unaffected by 
CNV, the affected eyes contained a calcification and gaps in the Bruch’s membrane.64 
Further, eyes with neovascular AMD exhibit thinner and more interrupted elastic layers 
(EL). EL is the layer between the collagenous zones, the two extracellular membranes of 
the RPE and Bruch’s membrane meet.  
 It should be stressed that advanced AMD can evolve in two different ways. One is 
geographic atrophy and the other is CNV.  Geographic atrophy is when the soft drusen 
coalesces and clusters together. These clusters form islands of photoreceptor cells that die 
and lead to scarring and vision loss. (There is no current treatment for geographic atrophy 
so this is beyond the scope of this paper.) CNV leads to wet AMD, but in advanced dry 
AMD, CNV doesn’t occur.65 Rather, the RPE cells die, and macular scarring occurs. In 
advanced dry AMD, there may be Bruch’s membrane damage and/or calcification, but it 
doesn’t lead to CNV.66  
 One last component that initiates CNV is the activation of the immune response 
and the aggregation of macrophages in the Bruch’s membrane.67 Several factors have 
been characterized whose dysfunction leads to a weakening of the Bruch’s membrane and 
allows the distressed RPE cells to not only release pro-angiogenic factors but activate an 
immune response. Three adult-onset, autosomal dominant diseases share retinal 
degeneration similar to that observed in AMD: Sorsby fundus dystrophy, late-onset 
retinal degeneration (LORD), and malattia leventinese-Doyne honeycomb retinal 
dystrophy (ML-DH).68  
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Researchers have isolated the mutations causing these disorders.  The anti-
angiogenic factors include: TIMP-3 in Sorsby’s, CTRP-5 in LORD, and EFEMP1 in ML-
DH. TIMP3 is a tissue inhibitor of metalloproteinases, while CTRP-5 and EFEMP1 are 
extracellular matrix proteins. Mutations in these genes leave the shared basal lamina of 
the RPE and Bruch’s membrane vulnerable. Gaps and damage to Bruch’s membrane 
observed in these diseases share a similar pathway to that seen in wet AMD, and all three 
have the potential to advance to CNV.  
In Sorsby and LORD, the basal lamina of the RPE fills up with lipid deposits and 
the RPE cells atrophy. The thickened basal lamina deposit is due to the accumulation of 
O-binding lipid. In LORD eyes, drusen deposits contain EC, UC, and apoB within the 
basal laminar of the RPE. (EC, UC and apoB are proteins involved in the immune 
response.)69  Due to the shared phenotypes with wet AMD, the thickening of the basal 
laminar deposit has been implicated as a major cause in CNV. Though it was initially 
speculated that the lipids found in basal laminar deposit were LDL cholesterol deposits, 
current research suggests that these are native lipoproteins caught in transit from the RPE 
to the choricocapillaries.70  
In ML-DH, drusen is observed distributed radially throughout the retina along 
with fatty deposits located around the optic nerve, in the back of the eye.71 In wet AMD, 
the drusen deposits are located exclusively in the macula. These disorders provide some 
insight into the factors that malfunction during AMD’s progression from dry to wet. It 
seems that the deposition of fats in the Bruch’s membrane hinders movement of solutes 
between the RPE and choroid and increases the risk of RPE stress and/or detachment.72  
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Oxidation of these lipids activates an inflammatory response, overexpression of 
VEGF from the distressed RPE, that leads to CNV in wet AMD.73 Studies have shown 
macrophage aggregation in and around these gaps in Bruch’s membrane.74 After 
infiltration, the macrophages only increase damage to the membrane and the RPE’s basal 
lamina as they release their own metalloproteinases and collagenases to access and 
phagocytose the fatty deposits. In this way, activation of the immune response and 
clustering of phagosomes to further compromise Bruch’s membrane is necessary for the 
initiation of CNV in AMD.75  
CURRENT/DEVELOPING  DIAGNOSTIC TECHNOLOGY AND TOOLS USED TO 
DETECT AND MONITOR AMD 
In the past decade, there has been extensive research in understanding, diagnosing 
and, ultimately, treating AMD.  In particular, as scientists and practitioners have become 
more knowledgeable about the role of lipofuscin, there has been a great deal of activity 
aimed at quantifying and tracking the accumulation of lipofuscin in the retina for 
degenerative disorders. This has led to the refinement of diagnostic tools, methods and 
technology, which has been instrumental in helping researchers understand and diagnose 
the progression of retinal disease, including AMD.  
In the discussion that follows, the paper will outline these technologies/techniques 
and explore their current efficacy and potential in AMD research.  
(1) Fluorescein Angiography  
Imaging has become a crucial tool in assessing the state of the retina and 
progression of retinal disease. The most basic modality is color fundus photography, 
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which produces high quality color photographs for diagnosis and future follow-up of 
retinal disease.  Closely related to this is Fluorescein Angiography (See Figure 4), which 
employs a modified fundus camera with excitation and barrier filters.76  Fluorescein (a 
dye) is injected intravenously into patient’s arm vein and sequential photographs are 
taken capturing the flow of fluorescein through the retinal and choroidal circulation.77  
This dye is a xanthene derivative with an absorbance spectrum of 450-490 nanometers 
and an emittance of 520-530. This molecule binds to plasma proteins—mostly albumin, a 
carrier protein in the blood—and red blood cells. The pattern of fluorescence allows 
practitioners to diagnose and follow the progression of vascular diseases of the retina, 
RPE and choroid.   These modalities have been in wide spread use since the late 1950’s 
and early 1960’s.78 
 
(2) Indocyanine Green Angiography  
A related imaging technique is Indocyanine Green Angiography which employs 
intravenously-injected ICG.  ICG is a tricarbicyanine derivative with an absorbance of 
799 to 850 nanometers and an emittance of 830 to 840 nanometers. It binds best to 
globulins, large molecular complexes with proteins. This technique images different 
vascular structures within the choroid and retina from those visualized by Fluorescein 
Angiography. This is because the dye used in fluorescein angiography flows better 
through the smaller retinal vessels and can pass between the fused basal lamina of the 
RPE/Bruch’s membrane while ICG binds to larger molecules and shows up much better 
in the choroidal circulation. For this reason, fluorescein angiography images retinal and 
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subretinal vasculature while ICG is used for underlying choroid. However, ICG imaging 
technique is generally used in conjunction with fluorescein angiography but its use is 
limited by its expense, patient side effects, and uneven access to the dye.  ICG 
Angiography has been in use since the 1990’s.79  
These techniques allow early visualization of abnormal blood vessel growth in the 
retina and choroid but have the limitation of being invasive, expensive and having no 
quantitative value in assessing disease progression.  These techniques have proven 
uneven in their ability to predict a high risk for future progression from dry to wet 
AMD.80 
(3) Quantitative Fundus Autofluorescence Imaging 
 A newer technique, Quantitative Fundus Autofluorescence (QAF) Imaging is a 
non-invasive approach in measuring lipofuscin accumulation in the retina.81 In this 
approach, a confocal scanning laser ophthalmoscope emits a 488 nanometer wavelength 
laser into the eye that reflects images from the retina and the choroid shown into the 
patient’s eye.  No dye is used. The process enables practitioners and researchers to 
actually see the retina deteriorating. This approach is currently being used to diagnose 
and track drusen and CNV in AMD.82  
In quantitative fundus autofluorescence imaging, this same laser and imaging 
technique is utilized. In contrast to color photography, fluorescein and ICG angiography, 
QAF appears to offer a way of predicting progression of patients with AMD to advanced 
dry or wet disease.83   QAF imaging uses the double conjugated structure of lipofuscin’s 
components to quantify the overall brightness of the retina. The excitation maxima of 
 22 
!
lipofuscin fluorophores vary from 440 to 510 nm, but they have similar emission maxima 
(600 nm), which matches that of fundus autofluorescence.84 The confocal scanning laser 
ophthalmoscope is outfitted with an internal reference to compare laser power and 
detector gain during imaging. Immediately after a laser bleaches the bisretinoids, a 
picture is generated, and a computer program analyzes the brightness of mean grey levels 
throughout the fundus to yield a value, which consists of a ratio between the grey value 
of the fundus and reference. This analysis takes into account laser strength, degree of 
pixilation, artifacts, and any eye movement to yield a value of brightness.85 This 
brightness relates to lipofuscin accumulation.86  
Quantitative fundus autofluorescence imaging has been performed on mouse 
models, cell cultures, and patients to non-invasively track the accumulation of lipofuscin. 
Papers have shown that RPE lipofuscin accumulation, shown by increased fundus 
autofluorescence, precedes geographic atrophy in the retina.87 Other studies done on 
Abca4 null mice show hyperautofluorescence in areas correlating to a thickening of the 
Bruch’s membrane due to basal laminar deposits.88 A recent 2014 study done on mice 
modeled after Retinitis Pigmentosa (RP) illustrated the accumulation of lipofuscin 
fluorophores in areas of atrophying and sick photoreceptor cells, and, in a 2012 study, 
mice induced with an experimental retinal detachment also showed bright 
hyperfluorescent rosettes.89 Clinically, elevated autofluorescence has been associated 
with scotomas associated with acute macular neuroretinopathy or from rings observed in 
the fundus of RP patients.90 In recessive Stargardts, studies have shown that the 
accumulation of lipofuscin precedes RPE cell atrophy and vision loss.91 The location of 
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lipofuscin in the retina can foreshadow retinal dysfunction before RPE and photoreptor 
cell death or a compromised Bruch’s membrane.92 
 
Figure 5. Autofluorescence Image of Geographic Atrophy in AMD. Unlike a fluorescein angiography, the 
metabolism of the vessels isn’t shown, but a diagnostician can see the accumulation of lipofuscin (light 
grey areas) and the presence of lipofuscin granules commonly seen in lesions located around the macula. 
Also areas of geographic atrophy are striking—seen here in the center over the patient’s fovea. Central RPE 
atrophy is common in AMD and Stargardt’s Disease also. Images provided by Dr. Thomas E. Flynn M.D. 
 
Much research has been performed on genetic retinal diseases with this approach 
to illustrate the changes of lipofuscin during the disease’s onset. Many computer 
programs have been created to compare quantitative fundus autofluorescence values 
generated from different patients, institutes, or imaging equipment. QAF has been done 
since the late 1990’s. 
(4) High Performance Liquid Chromatography Measurement of A2E 
High Performance Liquid Chromatography (HPLC) is an invasive technique 
performed on donor eyes, mouse models, and cell cultures to measure the amount of A2E 
in the eye. Lipofuscin consists of different bisretinoids.93 Researchers have just begun to 
understand how these waste products can turn toxic through photodegradation and photo-
oxidation. Photodegradation breaks down all the lipofuscin fluorophores (A2E among 
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them) to molecular fragments; some of these fragments are dicarbonyls that react with 
and damage protein to form products that incite the inflammation pathway and are 
numerous in drusen deposits.94 Studies have shown that A2E is less prone to oxidation 
than the other fluorophores (so it is more resistant to change its structure and not be 
detected during chemical analysis). Studies have shown that oxidized A2E doesn’t 
accumulate with age like the other fluorophores although A2E on its own accumulates 
and is a good reflection of lipofuscin in the retina.95 This makes the measurement of A2E 
fairly straightforward—as its chemical structure is more resistant to changes due to 
visible or UV light exposure.  
By itself, A2E in the retina has been shown to incite complement activation and 
inhibit the autophagic pathway.96 (Autophagy refers to the programmed cell death 
without an inflammatory response—i.e. apoptosis of sick cells rather than necrosis.)  
The measurement of A2E through HPLC analysis has been linearly correlated 
with quantitative autofluorescence values.97 This approach allows for an invasive 
chemical analysis of lipofuscin to correlate with quantitative autofluorescent imaging 
values.  
 (5) Optical Coherence Tomography 
 Optical Coherence Tomography (OCT) allows practitioners and researchers to 
track the thickness and morphology of the five retinal layers, RPE, Bruch’s membrane 
and the choroid and its vessels.98  This technique allows both anatomical and quantitative 
assessment of changes in the retina and choroid. OCT uses a similar approach as does an 
ultrasound and provides a picture of the membranes and their relative thicknesses.99 OCT 
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uses a scanning laser exciter and detector that sweeps extremely thin slices of retina and 
choroid.  This rapid scanning of the retina allows a three-dimensional picture of the retina 
and choroid to be reproduced in real time.100  The laser is used analogously to the way 
sound waves are used in ultrasound to produce an image. The extremely small 
wavelength of laser and improvements in detection and computer power are allowing 
imaging of structures at almost a single cell level.  The newest OCT machines permit 
imaging of individual arterial, venular, and capillary vessels at any given moment.  This 
modality called OCT angiography permits users to evaluate and track blood vessel 
growth in the eye without injection of expensive and risky dyes.101  Again, no predictive 
value for OCT or OCT angiography has yet been demonstrated.   
Current research on mouse models has correlated an increase in A2E 
accumulation and quantitative autofluorescence imaging values (i.e. increased retinal 
brightness) with a thinning of the photoreceptor cell layer.102 OCT provides a non-
invasive and efficient way of tracking the degeneration of the retina—while imaging and 
HPLC analysis has shown an increase in lipofuscin accumulation to this degeneration.  
Before the advent of OCT, researchers relied on histology to track retinal 
thickness, but OCT allows for the tracking of retinal disease in a mouse model over the 
course of its life.   
 (6) Conclusion 
 Standard imaging techniques, including color photography, Fluorescein and ICG 
angiography, OCT and OCT angiography permit clinicians and researchers to accurately 
distinguish dry from wet AMD and assess the success or failure of therapeutic 
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interventions (discussed below).  However, none of these imaging modalities offers a 
predictive capacity for quantitatively assessing risk of progression of disease.  Based 
upon current research and technology, it appears that QAF is the most promising, non-
invasive technique for assessing the progression of AMD and other retinal diseases and 
abnormalities. In addition, mouse studies should be pursued to consider the progress of 
lipofuscin accumulation over time. 
 
TREATMENT THERAPIES FOR AMD 
 Two decades ago, a diagnosis of wet AMD meant imminent blindness.  While 
there were surgical procedures that were used, the success and prognosis was poor. Over 
the past decade, wet AMD has become treatable, with vision improvement achieved in 
the vast majority of cases.   
This section will discuss the alternative therapies used for AMD, beginning with 
the disastrous surgical experiments, and culminating with the current injection protocol 
that has led to the improvement and retention of eye sight by thousands of elderly 
patients.  Currently, there are four approaches to treating AMD: thermal laser, 
photodynamic therapy, intraviteal anti-VEGF therapy, and investigational platelet-
derived growth factor inhibitor.  
(1) Surgical Approaches 
The first approach used to combat AMD was surgical.  In the United States, a 
procedure was developed that essentially took out the membrane.  However, while it 
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succeeded in removing the damaging accumulated lipofuscin, it also took out the RPE 
which led to the death of the retina.103  This strategy was quickly abandoned. 
In Germany, a scientist developed another surgical approach, in which a surgeon 
went into the eye and surgically repositioned the retina.104  This lengthy, aggressive and 
meticulous surgery proved only minimally successful and was similarly abandoned.105  
(2) Thermal Laser Therapy 
 After surgical alternatives were discredited, and before the development of 
intraviteal, anti-VEGF treatments, some practitioners used laser therapy as a way to treat 
AMD.  The theory was that a thermal laser could burn and kill tissue affected by CNV to 
prevent vessel growth.106 No specific wavelength of laser shows an advantage above 
others.107 Treatment produced a white retina causing necrosis of the retina, RPE, and 
choroid. Bleeding or hemorrhage of the choroid can occur but very rarely.108  
Excessive laser treatment comes with a risk of vision loss because the laser light 
energy kills the cells of the retina (therefore, it is recommended that burns be inflicted far 
from the macula), and treatment near the optic nerve can cause tissue necrosis. It is 
suggested that laser therapy be performed 100-200 microns from the optic nerve.109 This 
treatment runs the risk of permanent vision loss, and recurrence rates of the CNV are high 
because the RPE surrounding the burn release the same VEGF and signal distress. 
Studies have shown that no more than 15% of wet AMD patients derived any benefit 
from thermal laser therapy, and all patients lost vision after receiving the laser. A 
criterion for treatment was that patients should lose less vision with the laser treatment 
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than if their wet AMD were left untreated.110 Currently thermal laser therapy as a 
treatment for AMD isn’t recommended.  
 (3) Photodynamic Therapy 
 Until 1999, no treatment was as effective as thermal laser therapy against CNV 
until the advent of photodynamic therapy with verteporfin. In photodynamic therapy, a 
photosensitizing drug, verteporfin, is intravenously injected into the patient, and a low-
intensity (to minimize damage) infrared laser is emitted on the site of CNV to induce a 
photochemical reaction with the drug.111 This activates the circulating drug to injure 
adjacent cells and allows physicians to direct the attack on the new endothelial cells 
lining the choroidal vasculature. Despite targeting new growth in the choricocapillaries, 
anti-VEGF intravitreal injection still has been known to cause long-term macular scarring 
and central retinal damage accompanied by central vision loss in numerous cases.112  
The selective destructiveness of the photodynamic therapy made it more efficient 
than thermal laser therapy. Although retinal and choroidal tissue surrounding the CNV 
might be minimally disturbed, the RPE, choroid, and overlying sensory retina maintained 
their function. Rates of vision loss were much lower than those of AMD patients treated 
with thermal laser therapy.113   
Recurrence rates of CNV in photodynamic therapy were much lower than those 
experienced in thermal laser therapy, but patients needed to avoid bright light for 2 days 
after treatment before it could be ensured that the dye wouldn’t be activated to harm the 
tissue. Photodynamic therapy could prevent sight loss better than thermal laser therapy; 
however, it couldn’t be expected to improve or increase visual acuity that the patient had 
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already lost. The therapy also necessitated multiple treatments over a period of years—
for instance, a patient could be expected to have three treatments in the first year and two 
in the second.114  
 (4) Intravitreal Anti-VEGF Therapy 
 Both thermal laser therapy and photodynamic therapy couldn’t restore sight lost 
and were only approved for the treatment of CNV if the sight maintained would be better 
than if the condition were left untreated.  Both techniques provided limited benefit to 
patients and neither was used broadly by practitioners.115  However, the prognosis for 
treatment changed dramatically with the advent of anti-VEGF Therapy which was 
introduced nearly a decade ago.  Anti-VEGF Therapy would ultimately prove successful 
in restoring sight lost by CNV.  
 In the early stages of this therapy, pegaptanib sodium was injected into patients. 
This oligonucleotide binds to an isoform of vascular endothelial growth factor. This 
treatment wasn’t beneficial for CNV which had turned to scar, but early trials showed 
that it made a difference in 15% of cases in which the CNV was in an initial stage or 
hemorrhagic.116 However, the treatment needed to be done repeatedly, and this increased 
the occurrence of side effects—like endophthalmitis, a bacterial infection of the retina 
introduced by needle carrying skin bacteria into the eye—on patients. Some trials showed 
8% of patients in with induced endophthalmitis lost 6 or more lines of visual acuity.117  
 The introduction of ranibizumab as anti-VEGF therapy yielded much better trial 
results than pepaptanib sodium. Ranibizumab was a recombinant monoclonal antibody 
containing both mouse- and human-derived segments; this drug inhibits VEGF. This drug 
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is injected intravitreally (into the vitreous humor of the eye) on a monthly basis.118 Visual 
acuity improved (10.7 letters in the ranibizumab group compared to a loss of 9.8 letters in 
the pepaptanib sodium group after twenty-four months). Repeated injections of 
ranibuzumab included local ocular adverse effects (AEs), ranging from subconjunctival 
or vitreous hemorrhage and vitreous floaters to more serious like endophthalmitis. This is 
because VEGF inhibitors can stray into the general circulation and affect wound healing 
or prevent the formation of new blood vessels—which could be detrimental to a patient 
who had suffered from ischemia. AMD patients suffer high rates of cardiovascular 
disease, and anti-VEGF therapy is risky without close monitoring.119 However, there was 
no evidence that administration of ranibizumab increased systolic or diastolic blood 
pressure. Higher rates of hypertension were reported in patients undergoing 
photodynamic therapy (8.4%) than those under ranibizumab (6.4%). Because the drug 
contains mouse-derived proteins, some studies observed patients with antibodies formed 
to ranibizumab, but instances are rare and patients’ blood should be monitored for 
antibodies.120  
 Drugs inhibiting angiogenesis have been introduced to treat CNV since 
ramibizumab. A cheaper drug derived from similar antibody as that of ramibizumab, 
bevacizumab, was introduced into the market and showed similar (if slightly less 
impressive) success and low risk to the original antibody.121 In 2006, another anti-VEGF 
drug, aflibercept, was introduced to treat CNV. This recombinant fusion protein binds to 
VEGF receptors 1 and 2. In addition to treating wet AMD, aflibercept is also used to treat 
colorectal cancer. Repeated administration of aflibercept on a monthly basis yielded 
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equivalent results to ranibizumab.122 It should be noted that treatment with ranibizumab is 
the “gold standard” of anti-VEGF therapy, and newly introduced drugs’ antiangiogenic 
properties are compared to the original antibody’s patient outcomes in trials. 
 (5) Platelet-derived Growth Factor Inhibitor 
A new therapy for CNV that has been introduced works by preventing platelet-
derived growth factors from binding to their receptors; specifically, these new drugs for 
wet AMD target VEGF receptors on pericytes. One specifically, called Fovista, binds to a 
growth factor called PDGF-BB making it incompatible with the pericyte surface receptor 
PDGF-Beta.123 Pericytes are contractile cells that wrap around endothelial cells and 
reinforce the structure of capillaries and venules, and when unbound to blood vessels, 
they fall away from the endothelial cells.124 This makes the endothelial cells extremely 
vulnerable to anti-VEGF drugs. Platelet derived growth factor inhibitors are currently 
undergoing approval by the FDA and are in phase II of testing, but they have shown high 
success rates in early trials when used in concordance with anti-VEGF drugs.125  
 (6) Importance of Early Detection in CNV 
 The majority of CNV therapy relies on early detection of CNV growth. 
Fluorescein angiography studies have shown a proliferation rate of 10-18 microns per day 
in the initial stages of CNV. It is important to identify CNV lesions before they form 
beneath the foveal center, before they affect the patient’s line of vision. It is suggested 
that anti-VEGF therapy in instances of early detection can yield better levels of visual 
acuity in the patient after treatment.  
Mouse Model of Age-Related Macular Degeneration Study 
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 Due to the importance of early detection in treatment of AMD, this paper 
proposes a study tracking lipofuscin accumulation and retinal degeneration on an AMD 
mouse model.  The author of this paper worked on a study that shows the extraordinary 
potential for garnering data on AMD from mouse study and research.  A description of 
the study follows.  
(1) 2014 Mouse Study 
  In 2014, a study was undertaken to track the progression of mice that had gene 
knockouts for both Rdh8 and Abca4.126 In the past decade, Abca4 null mice have been 
used as a model of Stargardts Disease, a juvenile onset macular degeneration. Stargardts 
is much less complex than AMD to replicate in the laboratory because its onset is linked 
to a single gene mutation in the ATP-binding casette of photoreceptor cells.127 This 
mutation prevents photoreceptor cells from depositing waste outside of their cytoplasm to 
be degraded by RPE cells, and it manifests itself in very similar ways clinically. 
However, although the Abca4 gene knockout has been shown to lead to an accumulation 
of lipofuscin and photoreceptor death,128 this model doesn't show the same Bruch's 
membrane thickening and basal laminar deposits normally seen in Stargardts and 
AMD.129  
In the 2014 study, an extra mutation was added in the RDH8 gene. These genes 
(currently, there are four known) code for enzymes that reduce the waste products of the 
visual cycle before they are transported from the cytoplasm of the photoreceptor cells to 
be degraded by the lysosomes of the RPE cells.130 RDH8 specifically refers to an enzyme 
that reduces all-trans-retinal to all-trans-retinol with NADPH as a co-factor.131 This all-
 33 
!
trans-retinol is then transported out of the photoreceptor cell by the ATP-binding cassette 
transporter protein (coded by the Abca4 gene). 
 
Figure 7. QAF Measurement in Mouse Models. A fundus image of a mouse is taken. Levels of brightness 
are measured and averaged around the optic nerve (shown in black in the middle) to give each eye a 
corresponding qAF value. High QAF values have been shown to correspond to high levels of A2E in the 
eye. These QAF values give a non-invasive means of measuring the lipofuscin levels in the eye. Figures 
generated by the author. 
 
The 2014 study showed an earlier increased lipofuscin and A2E levels using both 
qAF and HPLC A2E analysis (see explanation of methods above). Photoreceptor death 
was preceded by heightened lipofuscin and A2E levels; in fact, 50% of photoreceptor 
thickness—measured by thinning of the outer nuclear layer in the retina through 
histology and OCT--occurred directly after a peak in lipofuscin and A2E was observed in 
the mice eyes. 
The 2014 study also noted a sudden and dramatic decrease in lipofuscin and A2E 
levels to correspond to the majority of photoreceptor cell death.132 This mimics results 
seen in Abca4 null mice and the Crb null mice (modeled after retinitis pigmentosa which 
similarly correlates high levels of lipofuscin and A2E located in areas of dramatic retinal 
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atrophy).133 However, despite the decrease of A2E, QAF values remained elevated. The 
study attributes this to the presence of bright autofluorescent rosettes in the photoreceptor 
cells of the double knockout mice. 
In addition, the thickening of Bruch's membrane which hadn't been observed in 
the Abca4 null mice manifested itself in the Rdh8/Abca4 null mice as rosettes of 
photoreceptor cells. Basal laminar deposits were correlated to these rosettes or semi-
circles of photoreceptor cells facing inwards from the RPE.134 These rosettes have been 
discovered and studied in mouse eyes.135  
Previously, a study correlated hyperfluorescent granules to these rosettes in mice 
with surgically detached retinas. This 2014 study used a cryostat of the double knockout 
mice to show similarly hyperfluorescent granules in the center of these sick photoreceptor 
cells. OCT and histological analysis supported these claims.136   
The 2014 study proposed that these hyperfluorescent granules might be excessive 
lipofuscin that was concentrated in the photoreceptor cells, but it could give no indication 
as to why these clustered rosettes of photoreceptor cells--which covered 1/10 to 1/4 of the 
mouse macula--were especially hyperfluorescent. Another theory posited was that this 
hyperfluorescence was so concentrated because it had been phagocytosed by 
macrophages or microglial cells, and the photoreceptor cell rosettes were formed around 
these clusters of immune cells.  
The 2014 study emphasized the need for closer analysis of the rosettes which generally 
emerged after the peak and sudden decrease of lipofuscin. These clusters dramatically 
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increased after a majority of overall photoreceptor death and retinal thinning had 
occurred.137  
(2) Potential for Further Study with Respect to AMD Progression 
Understanding the source of the hyperfluorescent rosettes might aid research in 
the pathway behind the immune system's role in Bruch's membrane thickening and the 
effects that make AMD so dramatic. The understanding of lipofuscin and A2E levels in 
the eye with regards to onset of AMD could also aid in early prevention or diagnosis in 
AMD.   
CONCLUSION 
Although much research has been done on the progression of genetic retinal 
diseases such as Stargardts, Retinitis Pigmentosa, and Best Villiform Disease in mice, 
very little has been done to observe the progression of lipofuscin in an AMD mouse 
model before and after the onset of AMd. Although lipofuscin is a known precursor and 
symptom of AMD, little is known about how its accumulation affects the progression of 
the disease.  
If a study could track and understand patterns in accumulation before even the 
progression to dry AMD, this could benefit current therapy greatly.  A study tracking 
lipofuscin in the retinas of the mice model before disease onset would permit researchers 
and physicians to gain a better understanding of the preceding patterns. Early detection is 
vital to the treatment and therapy of AMD. 
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